Cargando…

Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients

Background: The aim of this study was to investigate the efficacy of post-neoadjuvant chemotherapy (NAC) ultrasound (US), magnetic resonance imaging (MRI), and F-18fluorodeoxyglucose positron emission tomography (F-18 FDG-PET/CT) for detecting post-NAC axillary lymph node(ALN) metastasis in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Turan, Umit, Aygun, Murat, Duman, Berna Bozkurt, Kelle, Aygül Polat, Cavus, Yeliz, Tas, Zeynel Abidin, Dirim, Ahmet Baris, Irkorucu, Oktay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700016/
https://www.ncbi.nlm.nih.gov/pubmed/34943597
http://dx.doi.org/10.3390/diagnostics11122361
_version_ 1784620654117519360
author Turan, Umit
Aygun, Murat
Duman, Berna Bozkurt
Kelle, Aygül Polat
Cavus, Yeliz
Tas, Zeynel Abidin
Dirim, Ahmet Baris
Irkorucu, Oktay
author_facet Turan, Umit
Aygun, Murat
Duman, Berna Bozkurt
Kelle, Aygül Polat
Cavus, Yeliz
Tas, Zeynel Abidin
Dirim, Ahmet Baris
Irkorucu, Oktay
author_sort Turan, Umit
collection PubMed
description Background: The aim of this study was to investigate the efficacy of post-neoadjuvant chemotherapy (NAC) ultrasound (US), magnetic resonance imaging (MRI), and F-18fluorodeoxyglucose positron emission tomography (F-18 FDG-PET/CT) for detecting post-NAC axillary lymph node(ALN) metastasis in patients who had ALN metastasis at the time of diagnosis. Methods: This study included all breast cancer patients who received NAC for ALN metastasis; underwent axillary assessment with US, MRI, or F18FDG-PET/CT; and then were operated on in the General Surgery Clinic, Adana City Research and Training Hospital, Turkey. Patients’ data were recorded, including demographic data, clinicopathological parameters, NAC regimens, and operation types. The axillary response to chemotherapy on post-NAC US, MRI, and F-18 FDG-PET/CT was compared with the postoperative histopathological result of the ALN. Results: The study included a total of 171 female patients. The mean age of the patients was 53.28 ± 10.62 years. The post-NAC assessment revealed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of US for detecting ALN metastasis were 59.42%, 82.35%, 82.00%, and 60.00%, respectively, while the same measures regarding MRI for detecting ALN metastasis were 36.67%, 77.78%, 73.33%, and 42.42%, respectively. The sensitivity, specificity, PPV, and NPV of F-18FDG-PET/CT were 47.50%, 76.67%, 73.08%, and 52.27%, respectively. The evaluation of dual combinations of these three imaging techniques showed that the specificity and PPV of the combined use of US and F-18FDG-PET/CT was 100%. Conclusions: The results showed that US has the highest sensitivity and specificity for detecting ALN metastasis after NAC. Furthermore, ALND may be preferred for these patients instead of SLNB if both examinations simultaneously indicate lymph node metastasis in the post-NAC assessment with US and F-18 FDG-PET/CT. SLNB may be preferred if these two examinations simultaneously show a complete response.
format Online
Article
Text
id pubmed-8700016
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87000162021-12-24 Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients Turan, Umit Aygun, Murat Duman, Berna Bozkurt Kelle, Aygül Polat Cavus, Yeliz Tas, Zeynel Abidin Dirim, Ahmet Baris Irkorucu, Oktay Diagnostics (Basel) Article Background: The aim of this study was to investigate the efficacy of post-neoadjuvant chemotherapy (NAC) ultrasound (US), magnetic resonance imaging (MRI), and F-18fluorodeoxyglucose positron emission tomography (F-18 FDG-PET/CT) for detecting post-NAC axillary lymph node(ALN) metastasis in patients who had ALN metastasis at the time of diagnosis. Methods: This study included all breast cancer patients who received NAC for ALN metastasis; underwent axillary assessment with US, MRI, or F18FDG-PET/CT; and then were operated on in the General Surgery Clinic, Adana City Research and Training Hospital, Turkey. Patients’ data were recorded, including demographic data, clinicopathological parameters, NAC regimens, and operation types. The axillary response to chemotherapy on post-NAC US, MRI, and F-18 FDG-PET/CT was compared with the postoperative histopathological result of the ALN. Results: The study included a total of 171 female patients. The mean age of the patients was 53.28 ± 10.62 years. The post-NAC assessment revealed that the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of US for detecting ALN metastasis were 59.42%, 82.35%, 82.00%, and 60.00%, respectively, while the same measures regarding MRI for detecting ALN metastasis were 36.67%, 77.78%, 73.33%, and 42.42%, respectively. The sensitivity, specificity, PPV, and NPV of F-18FDG-PET/CT were 47.50%, 76.67%, 73.08%, and 52.27%, respectively. The evaluation of dual combinations of these three imaging techniques showed that the specificity and PPV of the combined use of US and F-18FDG-PET/CT was 100%. Conclusions: The results showed that US has the highest sensitivity and specificity for detecting ALN metastasis after NAC. Furthermore, ALND may be preferred for these patients instead of SLNB if both examinations simultaneously indicate lymph node metastasis in the post-NAC assessment with US and F-18 FDG-PET/CT. SLNB may be preferred if these two examinations simultaneously show a complete response. MDPI 2021-12-14 /pmc/articles/PMC8700016/ /pubmed/34943597 http://dx.doi.org/10.3390/diagnostics11122361 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Turan, Umit
Aygun, Murat
Duman, Berna Bozkurt
Kelle, Aygül Polat
Cavus, Yeliz
Tas, Zeynel Abidin
Dirim, Ahmet Baris
Irkorucu, Oktay
Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title_full Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title_fullStr Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title_full_unstemmed Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title_short Efficacy of US, MRI, and F-18 FDG-PET/CT for Detecting Axillary Lymph Node Metastasis after Neoadjuvant Chemotherapy in Breast Cancer Patients
title_sort efficacy of us, mri, and f-18 fdg-pet/ct for detecting axillary lymph node metastasis after neoadjuvant chemotherapy in breast cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8700016/
https://www.ncbi.nlm.nih.gov/pubmed/34943597
http://dx.doi.org/10.3390/diagnostics11122361
work_keys_str_mv AT turanumit efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT aygunmurat efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT dumanbernabozkurt efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT kelleaygulpolat efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT cavusyeliz efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT taszeynelabidin efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT dirimahmetbaris efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients
AT irkorucuoktay efficacyofusmriandf18fdgpetctfordetectingaxillarylymphnodemetastasisafterneoadjuvantchemotherapyinbreastcancerpatients